WFH provides Vietnam with Emicizumab drug for haemophilia treatment
PSNews - With efforts in improving the quality of treatment and comprehensive care for hemophilia patients as well as the proactive international cooperation activities of NIHBT and the Vietnam Association of Coagulation Disorders, WFH has selected Vietnam as one of the first countries to receive this drug.
Recently, the National Institute of Haematology and Blood Transfusion (NIHBT) announced that, the World Federation of Haemophilia (WFH) continued to provide Vietnam with 5,670 vials of Emicizumab, worth over 161 billion VND, with the aim of supporting for haemophilia treatment.
Haemophilia is an inherited genetic disorder that impairs the body’s ability to make blood clots, caused by decreased or abnormal function of coagulation factors VIII and IX. It can cause a person to bleed even without being injured for a long duration and repeat many times.
Currently, Emicizumab is considered an innovative prophylaxis for haemophilia A as it helps prevent and reduce the frequency of bleeding episodes in patients. Emicizumab was approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
With efforts in improving the quality of treatment and comprehensive care for hemophilia patients as well as the proactive international cooperation activities of NIHBT and the Vietnam Association of Coagulation Disorders, WFH has selected Vietnam as one of the first countries to receive this drug.
In 2021, Vietnam also received 4,410 vials of Emicizumab from WFH, worth 125 billion VND. The drug has been offered with free of charge to patients with haemophilia A.
As reported, although there is no current cure for haemophilia, early diagnosis and appropriate treatment can help the patients maintain their health and have an almost normal life. Injecting medicine regularly can help them avoid the risk of bleeding in daily life.
